Evaluation of toxicity by monitoring cfDNA

DOI
  • ONO Ryuichi
    Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)
  • YAMAMOTO Yusuke
    Laboratory of Integrative Oncology, National Cancer Center Research Institute
  • NARUSE Mie
    Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS) Central Animal Division, National Cancer Center Research Institute
  • TANABE Shihori
    Division of Risk Assessment, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)
  • YOSHIOKA Yusuke
    Institute of Medical Science, Tokyo Medical University
  • AISAKI Ken-ichi
    Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)
  • HIROSE Akihiko
    Division of Risk Assessment, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)
  • OCHIYA Takahiro
    Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS) Laboratory of Integrative Oncology, National Cancer Center Research Institute Institute of Medical Science, Tokyo Medical University
  • HIRABAYASHI Yoko
    Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)
  • KITAJIMA Satoshi
    Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research (CBSR), National Institute of Health Sciences (NIHS)

Bibliographic Information

Other Title
  • cfDNAによる毒性評価

Abstract

<p>Cell free DNA (cfDNA) circulates in the blood. Since cfDNA is derived from the dead blood cells, it is also present in healthy person, however, ctDNA (circulating tumor DNA) released from cancer cells has a mutation in a cancer-related gene in the blood of cancer patients. In recent years, since ctDNA having a mutation in a cancer-related gene released from a tumor exists in the blood of a cancer patient, the development of liquid biopsy using cfDNA as a biomarker for carcinogenesis has been extensively promoted. </p><p>Since there are DNA methylation sites specific to various organs in the body, cfDNA with DNA methylation specific to the target organ would leak into the blood stream when the target organ is damaged. </p><p>Therefore, in this study, cfDNA with liver-specific DNA methylation was used as a liver injury-specific biomarker in the blood of male C57BL/6J mice orally administered with carbon tetrachloride (70 mg/kg) which could induce liver injury. </p><p>The liquid biopsy by using DNA methylation of cfDNA as biomarkers would accelerate a rapid evaluation of chemical substances and drugs in Nonclinical Safety Evaluation.</p>

Journal

Details 詳細情報について

Report a problem

Back to top